MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells
MetadataShow full item record
CitationWang, Y., Y. Lee, L. Baitsch, A. Huang, Y. Xiang, H. Tong, A. Lako, et al. 2014. “MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells.” eLife 3 (1): e01763. doi:10.7554/eLife.01763. http://dx.doi.org/10.7554/eLife.01763.
AbstractDespite marked advances in breast cancer therapy, basal-like breast cancer (BBC), an aggressive subtype of breast cancer usually lacking estrogen and progesterone receptors, remains difficult to treat. In this study, we report the identification of MELK as a novel oncogenic kinase from an in vivo tumorigenesis screen using a kinome-wide open reading frames (ORFs) library. Analysis of clinical data reveals a high level of MELK overexpression in BBC, a feature that is largely dependent on FoxM1, a master mitotic transcription factor that is also found to be highly overexpressed in BBC. Ablation of MELK selectively impairs proliferation of basal-like, but not luminal breast cancer cells both in vitro and in vivo. Mechanistically, depletion of MELK in BBC cells induces caspase-dependent cell death, preceded by defective mitosis. Finally, we find that Melk is not required for mouse development and physiology. Together, these data indicate that MELK is a normally non-essential kinase, but is critical for BBC and thus represents a promising selective therapeutic target for the most aggressive subtype of breast cancer. DOI: http://dx.doi.org/10.7554/eLife.01763.001
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:12406532
- FAS Scholarly Articles 
- HMS Scholarly Articles 
Contact administrator regarding this item (to report mistakes or request changes)